Compare Moderna, Inc. (MRNA) vs Orion Office REIT Inc (ONL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Orion Office REIT Inc — how do they compare? Moderna, Inc. trades at $63.53 (market cap $24.18B), while Orion Office REIT Inc trades at $2.83 (market cap $158.01M). The key difference: Moderna, Inc. is far larger — about 153× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 2.89% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | ONL | |
|---|---|---|
Market Cap | $24.18B | $158.01M |
Sector | Health | Real Estate |
52-Week High | $81.80 | $3.04 |
52-Week Low | $22.36 | $1.93 |
Enterprise Value | $20.33B | $574.95M |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
ONL trades at $2.76, up 0.36% today, with a bullish technical signal from moving averages. The company reported a Q2 2026 EPS beat of $0.42 versus -$0.07 expected, but maintains negative net income and ROE. Revenue has declined from $208M in 2022 to $148M in 2025, with a net loss of -$139M. Analyst consensus is split evenly between Buy and Hold.
The outlook remains challenged by persistent losses and declining revenue, though the low P/B of 0.25 suggests asset value. Key risks include high debt and weak profitability. Upside depends on successful portfolio repositioning and a return to sustained earnings growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Orion Office REIT Inc
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →
